PI3K/mTOR Inhibitor-7 has potential for the research of cancer diseases; it significantly inhibits the PI3K/Akt/mTOR signaling pathway at 10 μM and exhibits potent dual inhibitory activity against PI3K and mTOR, with 4.7-fold greater potency than the positive control gedatolisib (IC50 = 0.3 vs. 1.4 μM).